An interventional study of COLLAGEN (COL) and PLACEBO (PLA) in Pain, Acute, Pain, Chronic and Knee Osteoarthritis, sponsored by Francisco Javier Martínez Noguera. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-06.
Sponsored by Francisco Javier Martínez Noguera · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Acute Pain with a site in Spain — 4 open to participants now, 5 under way, none of them phase 3. Acute Pain · Spain.
Among the 20 studies in Acute Pain with a site in Spain, this one is the 12th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2023, is one of 11 with no phase, and was the 15th registered.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →4 of the 20 studies in Acute Pain with a site in Spain are open now. Recruiting first, the newest first:
Fundacin Biomedica Galicia Sur · Sites in Spain
Ages 18+ · Healthy volunteers
Hospital General Universitario de Valencia · Sites in Spain
Ages 18+
Germans Trias i Pujol Hospital · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 86 across 905 interventional studies indexed under Acute Pain.
Median enrollment 160 across the 19 interventional studies, 107 across the 1 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Francisco Javier Martínez Noguera is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Francisco Javier Martínez Noguera has 1 study filed under Acute Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Acute Pain with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study evaluates the effect of taking a hydrolyzed collagen-based supplement on pain, function and quality of life in a moderately physically active population. Non-pathological knee pain is a common occurrence in many healthy people and can limit the quality of life. Therefore, the resolution of this problem can bring many benefits in terms of quality of life.
Study design
Randomized, double-blind, placebo-controlled clinical trial with 2 parallel study groups (collagen-based formulation and placebo). Participants will take the study products for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group will intake 10 g/day of a hydrolyzed collagen-based supplement.
Dietary Supplement: COLLAGEN (COL)
Subjects in this group will intake 10 g/day of placebo (maltodextrin).
Dietary Supplement: PLACEBO (PLA)
The collagen-based supplement will be ingested every day for 12 weeks at the same time.
The placebo will be ingested every day for 12 weeks at the same time.
Intensity of knee pain
It will be measured using a 100 mm long horizontal visual analogue scale (VAS) on which the participant must mark the pain he/she feels with 0 being "none" and 100 being "the most intense pain he/she can imagine". Once the level of pain is marked on the horizontal line, the length is measured from 0 in millimetres with a millimetre ruler. The results will be evaluated according to three levels of pain based on the marked values: \<40 mm: Values below 40 mm indicate mild or mild moderate pain 40-60 mm: If the measurement is between 40 and 60 mm, the pain is considered moderate to moderate-severe \>60 mm: If the values are greater than 60 mm, the pain is considered severe to unbearable.
Time frame: Throughout study completion, an average of 12 weeks
Physical activity data
Intensity by applying the IPAQ questionnaire and type (running, cycling, climbing, tennis, football...).
Time frame: The following data will be recorded during the baseline visit
Demographic data
Age, sex, employment status (active, unemployed, retired, student ....).
Time frame: The following data will be recorded during the baseline visit
Frequency of alcohol and tobacco consumption
Alcohol consumption and tobacco consumption (grams of alcohol and cigarettes per week)
Time frame: The following data will be recorded during the baseline visit
Weight
It will be measured by means of a precision balance (kg)
Time frame: The following data will be recorded during the baseline visit
Height
It will be measured by means of a stadiometer (cm)
Time frame: The following data will be recorded during the baseline visit
Body mass index
It will be calculated by the following formula kg/m2
Time frame: The following data will be recorded during the baseline visit
Clinical data
Symptoms are unilateral (Yes/No), Other joint problems (back, hand, neck, feet, shoulder, hip)
Time frame: The following data will be recorded during the baseline visit
Current analgesic medication:
Medication that has been taken at least once a week during the previous month. The name or active ingredient of the drug, dosage and frequency should be indicated.
Time frame: The following data will be recorded during the baseline visit
Number of participants taking medication
During the study, both the increase or reduction of chronic analgesic medication taken by the participant for pain management and the intake of new rescue medication, which is medication taken occasionally for symptomatic or symptom management, treatment of crises or exacerbations, will be recorded.
Time frame: Throughout study completion, an average of 12 weeks
Knee range of motion (ROM)
To assess ROM, the participant will be placed in a prone position on a stretcher. An electrogoniometer will then be placed on the leg to be assessed (affected leg) and the participant will be asked to voluntarily flex as far as possible or until pain is felt.
Time frame: Throughout study completion, an average of 12 weeks
WOMAC scale to measure pain, functional capacity and impact on quality of life
The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire is used to assess participants' perceived clinical changes in knee pain, stiffness and function.
Time frame: Throughout study completion, an average of 12 weeks
Quality of Life Questionnaire SF-36
The SF-36 health questionnaire is composed of 36 items that aim to collect all relevant aspects to characterize the health of an individual.
Time frame: Throughout study completion, an average of 12 weeks
KOOS Questionnaire for Knee Assessment
The Knee Injury and Osteoarthritis Outcome Score (KOOS) has been developed as an instrument to assess the patient's opinion of their knee and associated problems. The scores for each dimension are calculated by summing the responses to the relevant questions. The resulting scores are transformed into a scale from 0 to 100.
Time frame: Throughout study completion, an average of 12 weeks
Sleep quality using the Pittsburgh test
Sleep quality is assessed using the Pittsburgh sleep quality questionnaire. This questionnaire has 19 self-assessment questions and 5 questions addressed to the roommate or bed partner, with only the first 19 being used to obtain the overall score.
Time frame: Throughout study completion, an average of 12 weeks
Started Apr 2023 (actual). Primary completion is estimated for Feb 2024, 10 months after the start.
Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 10 months is below that.
Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Collagen
Francisco Javier Martínez Noguera